QNRX•benzinga•
Quoin Pharmaceuticals Announces Whole Body' Data From Ongoing Pediatric Netherton Syndrome Study; Says Both Key Clinical Endpoints Demonstrated Significant Clinical Improvements From Baseline After Two Weeks Of Treatment With QRX003
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 27, 2025 by benzinga